Abstract P3-08-61: The association of disease free survival and the impact of tumor subtype on overall survival in advanced breast cancer patients: A real-world study from the China National Cancer Center

Yiqun Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Zijing Wang(Qingdao University), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Peng Yuan, Yang Luo(Kunming University), Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiayu Wang(Second Hospital of Shandong University), Qiao Li(Guangzhou University of Chinese Medicine), Qing Li(Xiangnan University), Yimeng Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Pin Zhang(Peking University), Shaoyan Lin(Nanjing Agricultural University), Xiuwen Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruigang Cai(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cancer Research
February 15, 2020
10.1158/1538-7445.sabcs19-p3-08-61
Cited by 0

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743